STAT+: Drug pricing, Medicaid, and research funding: The key policy issues at stake in the midterms

Daniel covers the intersection of the health industry and the federal government. He reports on corporate influence in government, the health consequences of federal policies, and the politics of health care. Confidential tips can be sent on Signal at danielp.100.WASHINGTON — Health industry leaders, still contending with the new rules of President Trump’s Washington, are about to face another shift. November’s midterm elections are likely to shake up key health policy debates, from Medicaid funding to the price of medication. That’s especially true if Democrats seize control of a chamber of Congress, though any major policymaking would still need Trump’s signature. Drawing on interviews with nearly a dozen leaders and lobbyists representing the health industry, these are the most important questions about federal policy after the midterms. How they are answered will have wide-ranging impacts for America’s health system, science, and patients. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+. Already have an account? Log in View All Plans To read the rest of this story subscribe to STAT+. Subscribe